DE3886543D1 - Oligonukleotidfunktionierungsmittel und -verfahren. - Google Patents
Oligonukleotidfunktionierungsmittel und -verfahren.Info
- Publication number
- DE3886543D1 DE3886543D1 DE88908841T DE3886543T DE3886543D1 DE 3886543 D1 DE3886543 D1 DE 3886543D1 DE 88908841 T DE88908841 T DE 88908841T DE 3886543 T DE3886543 T DE 3886543T DE 3886543 D1 DE3886543 D1 DE 3886543D1
- Authority
- DE
- Germany
- Prior art keywords
- methods
- oligonucleotide
- functioning agents
- agents
- oligonucleotide functioning
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/04—Saturated ethers
- C07C43/10—Saturated ethers of polyhydroxy compounds
- C07C43/11—Polyethers containing —O—(C—C—O—)n units with ≤ 2 n≤ 10
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/14—Unsaturated ethers
- C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
- C07D317/22—Radicals substituted by singly bound oxygen or sulfur atoms etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2408—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyalkyl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2433—Compounds containing the structure N-P(=X)n-X-acyl, N-P(=X)n-X-heteroatom, N-P(=X)n-X-CN (X = O, S, Se; n = 0, 1)
- C07F9/2441—Compounds containing the structure N-P(=X)n-X-acyl, N-P(=X)n-X-heteroatom, N-P(=X)n-X-CN (X = O, S, Se; n = 0, 1) containing the structure N-P(=X)n-X-C(=X) (X = O, S, Se; n = 0, 1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2479—Compounds containing the structure P(=X)n-N-acyl, P(=X)n-N-heteroatom, P(=X)n-N-CN (X = O, S, Se; n = 0, 1)
- C07F9/2487—Compounds containing the structure P(=X)n-N-acyl, P(=X)n-N-heteroatom, P(=X)n-N-CN (X = O, S, Se; n = 0, 1) containing the structure P(=X)n-N-C(=X) (X = O, S, Se; n = 0, 1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/26—Amides of acids of phosphorus containing P-halide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/5537—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom the heteroring containing the structure -C(=O)-N-C(=O)- (both carbon atoms belong to the heteroring)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/335—Polymers modified by chemical after-treatment with organic compounds containing phosphorus
- C08G65/3356—Polymers modified by chemical after-treatment with organic compounds containing phosphorus having nitrogen in addition to phosphorus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/104,200 US4914210A (en) | 1987-10-02 | 1987-10-02 | Oligonucleotide functionalizing reagents |
PCT/US1988/003212 WO1989002931A1 (en) | 1987-10-02 | 1988-09-19 | Oligonucleotide functionalizing reagents and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
DE3886543D1 true DE3886543D1 (de) | 1994-02-03 |
DE3886543T2 DE3886543T2 (de) | 1994-04-21 |
Family
ID=22299185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE88908841T Expired - Fee Related DE3886543T2 (de) | 1987-10-02 | 1988-09-19 | Oligonukleotidfunktionierungsmittel und -verfahren. |
Country Status (8)
Country | Link |
---|---|
US (1) | US4914210A (de) |
EP (1) | EP0380559B1 (de) |
JP (1) | JP2714090B2 (de) |
CA (1) | CA1310600C (de) |
DE (1) | DE3886543T2 (de) |
IE (1) | IE61046B1 (de) |
IL (1) | IL87879A (de) |
WO (1) | WO1989002931A1 (de) |
Families Citing this family (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5359100A (en) * | 1987-10-15 | 1994-10-25 | Chiron Corporation | Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers |
US5082780A (en) * | 1989-09-12 | 1992-01-21 | Eastman Kodak Company | Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures |
US5254469A (en) * | 1989-09-12 | 1993-10-19 | Eastman Kodak Company | Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures |
US5272077A (en) * | 1989-09-12 | 1993-12-21 | Eastman Kodak Company | Method for preparing a covalent conjugate of an oligonucleotide and an enzyme |
US5410068A (en) * | 1989-10-23 | 1995-04-25 | Perseptive Biosystems, Inc. | Succinimidyl trityl compounds and a process for preparing same |
US6753423B1 (en) | 1990-01-11 | 2004-06-22 | Isis Pharmaceuticals, Inc. | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals |
US6395492B1 (en) | 1990-01-11 | 2002-05-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
US5578718A (en) * | 1990-01-11 | 1996-11-26 | Isis Pharmaceuticals, Inc. | Thiol-derivatized nucleosides |
US6114513A (en) | 1990-01-11 | 2000-09-05 | Isis Pharmaceuticals, Inc. | Thiol-derivatized oligonucleotides |
US7037646B1 (en) | 1990-01-11 | 2006-05-02 | Isis Pharmaceuticals, Inc. | Amine-derivatized nucleosides and oligonucleosides |
US6153737A (en) * | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
US5852182A (en) * | 1990-01-11 | 1998-12-22 | Isis Pharmaceuticals Inc. | Thiol-derivatized oligonucleosides |
US5236694A (en) * | 1990-02-21 | 1993-08-17 | The Board Of Regents, The University Of Texas System | 19f labelled dextrans and antibodies as nmr imaging and spectroscopy agents |
US5387505A (en) * | 1990-05-04 | 1995-02-07 | Eastman Kodak Company | Preparation and isolation of single-stranded biotinylated nucleic acids by heat avidin-biotin cleavage |
US20060084797A1 (en) * | 1990-06-11 | 2006-04-20 | Gilead Sciences, Inc. | High affinity TGFbeta nucleic acid ligands and inhibitors |
US6147204A (en) * | 1990-06-11 | 2000-11-14 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
US6168778B1 (en) | 1990-06-11 | 2001-01-02 | Nexstar Pharmaceuticals, Inc. | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes |
US6465188B1 (en) | 1990-06-11 | 2002-10-15 | Gilead Sciences, Inc. | Nucleic acid ligand complexes |
US5155166A (en) * | 1990-06-18 | 1992-10-13 | Eastman Kodak Company | Use of 1-(1-pyrrolidinylcarbonyl)pyridinium salts to attach compounds to carboxylated particles and a kit containing same |
US5245022A (en) * | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
US5210015A (en) * | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
US5420330A (en) * | 1990-09-07 | 1995-05-30 | Pharmacia P-L Biochemicals Inc. | Lipo-phosphoramidites |
GB9021625D0 (en) * | 1990-10-04 | 1990-11-21 | Ici Plc | Synthesis of oligonucleotides |
US5200462A (en) * | 1991-01-25 | 1993-04-06 | Eastman Kodak Company | Succinimide containing polymers and lattices prepared from same |
CA2065719A1 (en) | 1991-04-30 | 1992-10-31 | John B. Findlay | Nucleic acid amplification and detection methods using rapid polymerase chain reaction cycle |
US5495006A (en) * | 1991-09-27 | 1996-02-27 | Allelix Biopharmaceuticals, Inc. | Antiviral polynucleotide conjugates |
US6831166B2 (en) | 1992-10-23 | 2004-12-14 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
CA2117583A1 (en) * | 1992-03-17 | 1993-09-30 | Alberto Haces | Modified nucleotides |
CA2150903A1 (en) * | 1992-12-04 | 1994-06-23 | American Home Products Corporation | Compounds for the treatment of leukemias |
US20060257885A1 (en) * | 1993-01-05 | 2006-11-16 | Gelfand David H | Homogeneous assay system |
US6653458B1 (en) | 1993-09-03 | 2003-11-25 | Isis Pharmaceuticals, Inc. | Modified oligonucleotides |
US5622822A (en) | 1994-09-13 | 1997-04-22 | Johnson & Johnson Clinical Diagnostics, Inc. | Methods for capture and selective release of nucleic acids using polyethyleneimine and an anionic phosphate ester surfactant and amplification of same |
US5582988A (en) | 1994-09-15 | 1996-12-10 | Johnson & Johnson Clinical Diagnostics, Inc. | Methods for capture and selective release of nucleic acids using weakly basic polymer and amplification of same |
US5705366A (en) | 1994-09-15 | 1998-01-06 | Johnson & Johnson Clinical Diagnostics, Inc. | Coamplification of target nucleic acids using volume exclusion agent in reaction composition, test kit and test device useful therefor |
US8071737B2 (en) * | 1995-05-04 | 2011-12-06 | Glead Sciences, Inc. | Nucleic acid ligand complexes |
JP2809601B2 (ja) * | 1995-07-13 | 1998-10-15 | 株式会社分子バイオホトニクス研究所 | 塩基配列増幅方法 |
US5853990A (en) * | 1996-07-26 | 1998-12-29 | Edward E. Winger | Real time homogeneous nucleotide assay |
US6426335B1 (en) * | 1997-10-17 | 2002-07-30 | Gilead Sciences, Inc. | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
US6051698A (en) * | 1997-06-06 | 2000-04-18 | Janjic; Nebojsa | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
ES2228520T3 (es) * | 1999-05-04 | 2005-04-16 | Ortho-Clinical Diagnostics, Inc. | Capatura rapida y eficaz de adn de una muestra sin usar reactivo de lisis celular. |
US6528254B1 (en) | 1999-10-29 | 2003-03-04 | Stratagene | Methods for detection of a target nucleic acid sequence |
EP1136569A3 (de) | 2000-03-24 | 2004-01-28 | Bayer Corporation | Nukleinsäuresonden, die hoch-hydrophile nicht-nukleosidische Gruppen mit multiplen Markern enthalten und ihre Verwendungen |
US7262006B1 (en) | 2000-05-01 | 2007-08-28 | Ortho-Clinical Diagnostics, Inc. | Rapid and efficient capture of DNA from sample without using cell lysing reagent |
JP2004507226A (ja) * | 2000-05-30 | 2004-03-11 | ピーイー コーポレイション (エヌワイ) | ライゲーションおよび増幅の組み合わせを用いて標的核酸を検出するための方法 |
US6743905B2 (en) * | 2001-04-16 | 2004-06-01 | Applera Corporation | Mobility-modified nucleobase polymers and methods of using same |
US20040106109A1 (en) * | 2001-10-02 | 2004-06-03 | Belly Robert T | Detection of ras mutations |
DK1487978T3 (da) * | 2002-03-15 | 2009-03-23 | Nuevolution As | Forbedret fremgangsmåde til syntese af templatemolekyler |
EP1534859B1 (de) | 2002-06-28 | 2010-11-24 | PrimeraDx, Inc. | Verfahren zum nachweis von sequenzunterschieden |
CA2498320A1 (en) * | 2002-09-20 | 2004-04-01 | Integrated Dna Technologies, Inc. | Anthraquinone quencher dyes, their methods of preparation and use |
US20040235005A1 (en) * | 2002-10-23 | 2004-11-25 | Ernest Friedlander | Methods and composition for detecting targets |
MXPA05010429A (es) | 2003-03-31 | 2005-11-04 | Hoffmann La Roche | Composiciones y metodos para detectar ciertos flavivirus que incluyen miembros del serogrupo del virus de la encefalitis japonesa. |
US20050239089A1 (en) * | 2003-06-06 | 2005-10-27 | Johnson Martin D | Mobility cassettes |
NZ617083A (en) * | 2003-08-27 | 2015-04-24 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
US7439341B2 (en) * | 2003-11-14 | 2008-10-21 | Integrated Dna Technologies, Inc. | Fluorescence quenching azo dyes, their methods of preparation and use |
US7939251B2 (en) | 2004-05-06 | 2011-05-10 | Roche Molecular Systems, Inc. | SENP1 as a marker for cancer |
CA2601554A1 (en) | 2005-05-20 | 2006-11-30 | Integrated Dna Technologies, Inc. | Compounds and methods for labeling oligonucleotides |
US7892795B2 (en) | 2005-08-02 | 2011-02-22 | Focus Diagnostics, Inc. | Methods and compositions for detecting BK virus |
MY162210A (en) * | 2006-04-03 | 2017-05-31 | Roche Innovation Ct Copenhagen As | Pharmaceutical composition |
ES2715625T3 (es) | 2006-04-03 | 2019-06-05 | Roche Innovation Ct Copenhagen As | Composición farmacéutica que comprende oligonucleótidos antisentido anti-miARN |
EP2450710B1 (de) | 2006-07-14 | 2020-09-02 | The Regents of The University of California | Krebsbiomarker und Anwendungsverfahren dafür |
ES2603379T3 (es) * | 2006-10-09 | 2017-02-27 | Roche Innovation Center Copenhagen A/S | Compuestos antagonistas de ARN para la modulación de PCSK9 |
DK2149605T3 (da) * | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Korte RNA antagonist forbindelser til modulering af det ønskede mRNA |
WO2008113830A1 (en) * | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | Rna antagonist compounds for the inhibition of apo-b100 expression |
DK2152879T3 (da) | 2007-05-01 | 2013-02-18 | Santaris Pharma As | RNA antagonistforbindelser til modulering af beta-catenin |
NZ581201A (en) | 2007-05-11 | 2012-05-25 | Enzon Pharmaceuticals Inc | Rna antagonist compounds for the modulation of her3 |
EP2198024A2 (de) * | 2007-08-30 | 2010-06-23 | Santaris Pharma A/S | Rna-antagonistenverbindungen zur modulation von fabp4/ap2 |
KR101889518B1 (ko) | 2007-10-04 | 2018-08-17 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | 마이크로MIRs |
US8450290B2 (en) * | 2007-11-26 | 2013-05-28 | Enzon Pharmaceuticals, Inc. | Methods for treating androgen receptor dependent disorders including cancers |
DK2225377T3 (da) * | 2007-11-26 | 2014-04-07 | Santaris Pharma As | Lna-antagonister, der er målrettet mod androgenreceptoren |
CA2707539A1 (en) * | 2007-12-03 | 2009-06-11 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of pik3ca expression |
US20090197254A1 (en) * | 2007-12-14 | 2009-08-06 | Ming-Chou Lee | Variant scorpion primers for nucleic acid amplification and detection |
CA2717792A1 (en) * | 2008-03-07 | 2009-09-11 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
ES2430590T3 (es) | 2008-05-14 | 2013-11-21 | Genomic Health, Inc. | Predictores de la respuesta de pacientes al tratamiento con inhibidores del receptor del EGF |
EP2315832B1 (de) | 2008-08-01 | 2015-04-08 | Roche Innovation Center Copenhagen A/S | Micro-rna-vermittelte modulation koloniestimulierender faktoren |
CN102216472A (zh) * | 2008-11-13 | 2011-10-12 | 里博克斯艾克斯有限公司 | Rna检测方法 |
EP2421970B1 (de) * | 2009-04-24 | 2016-09-07 | Roche Innovation Center Copenhagen A/S | Pharmazeutische zusammensetzungen zur behandlung von nicht auf interferon ansprechende hcv-patienten |
EP2256215A1 (de) | 2009-04-30 | 2010-12-01 | Steffen Mergemeier | Testsystem unter Verwendung einer Nukleaseaktivität einer Nukleinsäurepolymerase |
MX2011013078A (es) | 2009-06-12 | 2012-02-01 | Santaris Pharma As | Nuevos compuestos potentes antisentido anti apolipoproteina b (apob). |
US8563528B2 (en) | 2009-07-21 | 2013-10-22 | Santaris Pharma A/S | Antisense oligomers targeting PCSK9 |
WO2011034605A2 (en) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
EP2490699A1 (de) | 2009-10-20 | 2012-08-29 | Santaris Pharma A/S | Orale freisetzung von therapeutisch wirksamen lna-oligonukleotiden |
WO2011054811A1 (en) | 2009-11-03 | 2011-05-12 | Santaris Pharma A/S | Rna antagonists targeting hsp27 combination therapy |
US9506057B2 (en) | 2010-03-26 | 2016-11-29 | Integrated Dna Technologies, Inc. | Modifications for antisense compounds |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
EP2553123B1 (de) | 2010-03-26 | 2016-08-24 | Integrated DNA Technologies, Inc. | Verfahren zur verstärkung einer nukleinsäurehybridisierung |
US8536323B2 (en) | 2010-04-21 | 2013-09-17 | Pierce Biotechnology, Inc. | Modified nucleotides |
US9206216B2 (en) | 2010-04-21 | 2015-12-08 | Pierce Biotechnology, Inc. | Modified nucleotides methods and kits |
US8278049B2 (en) | 2010-04-26 | 2012-10-02 | Ann & Robert H. Lurie Children's Hospital of Chicago | Selective enrichment of CpG islands |
EP2564200B8 (de) | 2010-04-27 | 2019-10-02 | The Regents of The University of California | Krebsbiomarker und anwendungsverfahren dafür |
WO2012007477A1 (en) | 2010-07-12 | 2012-01-19 | Santaris Pharma A/S | Anti hcv oligomers |
WO2012033848A1 (en) | 2010-09-07 | 2012-03-15 | Integrated Dna Technologies, Inc. | Modifications for antisense compounds |
WO2012034942A1 (en) | 2010-09-13 | 2012-03-22 | Santaris Pharma A/S | Compounds for the modulation of aurora kinase b expression |
WO2012065051A1 (en) | 2010-11-12 | 2012-05-18 | Enzon Pharmaceuticals, Inc. | Compositions and methods for treating androgen receptor dependent disorders including cancers |
WO2012066093A1 (en) | 2010-11-19 | 2012-05-24 | Santaris Pharma A/S | Compounds for the modulation of pdz-binding kinase (pbk) expression |
WO2012066092A1 (en) | 2010-11-19 | 2012-05-24 | Santaris Pharma A/S | Compounds for the modulation of aurora kinase a expression |
JP6162044B2 (ja) | 2010-12-23 | 2017-07-12 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 結合剤 |
JP5766296B2 (ja) | 2010-12-23 | 2015-08-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用 |
CA2817928C (en) | 2010-12-23 | 2019-10-01 | Michael Gerg | Detection of a posttranslationally modified polypeptide by a bi-valent binding agent |
WO2012107537A1 (en) | 2011-02-09 | 2012-08-16 | Riboxx Gmbh | Method for the detection of polynucleotide sequences |
WO2012110457A2 (en) | 2011-02-14 | 2012-08-23 | Santaris Pharma A/S | Compounds for the modulation of osteopontin expression |
WO2012143427A1 (en) | 2011-04-19 | 2012-10-26 | Santaris Pharma A/S | Anti polyomavirus compounds |
WO2012175733A1 (en) | 2011-06-23 | 2012-12-27 | Santaris Pharma A/S | Hcv combination therapy |
KR20140058536A (ko) | 2011-06-30 | 2014-05-14 | 스텔라 에이피에스 | Hcv 조합 치료 |
WO2013000855A1 (en) | 2011-06-30 | 2013-01-03 | Santaris Pharma A/S | Hcv combination therapy |
WO2013068347A1 (en) | 2011-11-07 | 2013-05-16 | Santaris Pharma A/S | Prognostic method for checking efficacy of micro rna-122 inhibitors in hcv+ patients |
BR112014011018A2 (pt) | 2011-11-11 | 2017-05-02 | Santaris Pharma As | compostos para modulação de splining de smn2 |
MX2014009565A (es) | 2012-02-10 | 2014-11-10 | Genentech Inc | Anticuerpos monocatenarios y otros heteromultimeros. |
EP2828407A4 (de) | 2012-03-20 | 2016-02-10 | UNIVERSITé LAVAL | Nucleinsäurenachweisverfahren mit zielspezifischen indexierungssonden mit lösbarem segment für den nachweis mittels fluoreszenz bei der bindung an eine fangsonde |
ES2597228T3 (es) | 2012-06-27 | 2017-01-17 | F. Hoffmann-La Roche Ag | Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas |
WO2014001325A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
BR112015007606A2 (pt) | 2012-10-04 | 2018-01-30 | Univ Leland Stanford Junior | métodos e reagentes para a detecção, quantificação e serotipagem de vírus da dengue |
AU2013346767B2 (en) | 2012-11-15 | 2019-04-11 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
DK2922955T3 (da) | 2012-11-26 | 2019-05-13 | Roche Innovation Ct Copenhagen As | Sammensætninger og fremgangsmåder til modulering af FGFR3-ekspression |
PE20160158A1 (es) | 2013-06-27 | 2016-03-18 | Roche Innovation Ct Copenhagen As | Oligomeros antisentido y conjugados con diana en pcsk9 |
SG10201912985RA (en) | 2013-07-12 | 2020-02-27 | Ophthotech Corp | Methods for treating or preventing ophthalmological conditions |
EP3068783B1 (de) | 2013-11-15 | 2020-09-23 | The Board of Trustees of the Leland Stanford Junior University | Agonisten des hypokretin-rezeptors 2 zur verwendung zur behandlung von herzversagen |
GB201408623D0 (en) | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
WO2016024205A1 (en) | 2014-08-15 | 2016-02-18 | Pfizer Inc. | Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene |
PL3227332T3 (pl) | 2014-12-03 | 2020-06-15 | F. Hoffmann-La Roche Ag | Wielospecyficzne przeciwciała |
WO2016096938A1 (en) | 2014-12-16 | 2016-06-23 | Roche Innovation Center Copenhagen A/S | Chiral toxicity screening method |
EP3443123B1 (de) | 2016-04-11 | 2021-08-11 | Board of Regents, The University of Texas System | Verfahren und zusammensetzungen zum nachweis der affinität einzelner t-zellrezeptoren und sequenz |
WO2019219723A1 (en) | 2018-05-18 | 2019-11-21 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions for treatment of microrna related diseases |
WO2023077107A1 (en) | 2021-10-29 | 2023-05-04 | Sana Biotechnology, Inc. | Methods and reagents for amplifying viral vector nucleic acid products |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522735A (en) * | 1983-06-17 | 1985-06-11 | The B. F. Goodrich Company | Polyphosphoramidite oligomers and stabilizer compositions thereof |
US4617261A (en) * | 1984-03-21 | 1986-10-14 | Cetus Corporation | Process for labeling nucleic acids and hybridization probes |
US4582789A (en) * | 1984-03-21 | 1986-04-15 | Cetus Corporation | Process for labeling nucleic acids using psoralen derivatives |
-
1987
- 1987-10-02 US US07/104,200 patent/US4914210A/en not_active Expired - Lifetime
-
1988
- 1988-09-19 JP JP63508099A patent/JP2714090B2/ja not_active Expired - Fee Related
- 1988-09-19 EP EP88908841A patent/EP0380559B1/de not_active Expired - Lifetime
- 1988-09-19 WO PCT/US1988/003212 patent/WO1989002931A1/en active IP Right Grant
- 1988-09-19 DE DE88908841T patent/DE3886543T2/de not_active Expired - Fee Related
- 1988-09-27 CA CA000578519A patent/CA1310600C/en not_active Expired - Lifetime
- 1988-09-29 IL IL87879A patent/IL87879A/xx not_active IP Right Cessation
- 1988-09-30 IE IE297188A patent/IE61046B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0380559A1 (de) | 1990-08-08 |
JP2714090B2 (ja) | 1998-02-16 |
JPH03501383A (ja) | 1991-03-28 |
IE61046B1 (en) | 1994-09-07 |
IL87879A (en) | 1993-06-10 |
IL87879A0 (en) | 1989-03-31 |
WO1989002931A1 (en) | 1989-04-06 |
US4914210A (en) | 1990-04-03 |
IE882971L (en) | 1989-04-02 |
DE3886543T2 (de) | 1994-04-21 |
EP0380559B1 (de) | 1993-12-22 |
CA1310600C (en) | 1992-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3886543T2 (de) | Oligonukleotidfunktionierungsmittel und -verfahren. | |
DE3784521D1 (de) | Multiprozessorverfahren und -anordnung. | |
DE294214T1 (de) | Coexstrusions-vorrichtung und -verfahren. | |
NO912863D0 (no) | Bis-aza-bicykliske angstdempende midler. | |
DE3785855D1 (de) | Vermittlungsanordnung und -verfahren. | |
DE3869446D1 (de) | Desodorierungsmittel. | |
DE3785663D1 (de) | Loetgeraet. | |
FI882407A0 (fi) | Fibrinolytiska proteiner. | |
NO892617L (no) | Anti-aterogene midler. | |
DE3879014T2 (de) | Elektromagnet. | |
DE3861876D1 (de) | Vollformverfahren und -vorrichtung. | |
NO893141D0 (no) | Toey-kondisjoneringsmidler. | |
FI894850A0 (fi) | Avkyld tankkontainer. | |
DE3868474D1 (de) | Insektizides mittel. | |
ATE100094T1 (de) | Imidazolantiarrythmische mittel. | |
DE3861694D1 (de) | Cyclopropancarboxamide. | |
DE3853279T2 (de) | Laryngoskop. | |
DK35488A (da) | 3-aryl-5-alkylthio-4h-1,2,4-thiazoler, samt anvendelsen heraf | |
DE3765583D1 (de) | Oberflaechenbehandlungsmittel und -verfahren. | |
DE3860307D1 (de) | 2-aminomethyltetrahydrofurane. | |
DE3860710D1 (de) | Exklusiv-oder-schaltung. | |
FI883254A0 (fi) | Cytostatiskt aktiva antracyklinderivat. | |
DE3866770D1 (de) | Gerbstoff. | |
FI890204A0 (fi) | Unfodringselement och -konstruktion foer vaermebehandlingsugnar. | |
FI883253A0 (fi) | Cytostatiskt aktiva antracyklinderivat. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: CHIRON CORP. (N.D.GES.D. STAATES DELAWARE), EMERYV |
|
8327 | Change in the person/name/address of the patent owner |
Owner name: CHIRON DIAGNOSTICS CORP. (N.D.GES.D. STAATES DELAW |
|
8339 | Ceased/non-payment of the annual fee |